ATM polymorphism IVS62+60G>A is not associated with disease aggressiveness in prostate cancer

• Published in: Urology (Ridgewood, N.J.) N.J.), 2006-06, Vol.67 (6), p.1320-1323
• Main Authors: Lee Browning, Robert E., Li, Hecheng, Shinohara, Eric T., Cai, Qiuyin, Chen, Heidi, Courtney, Regina, Cao, Carolyn, Zheng, Wei, Lu, Bo
• Format: Article
• Language: English
• Subjects: Aged; Ataxia Telangiectasia Mutated Proteins; Biological and medical sciences; Cell Cycle Proteins - genetics; DNA-Binding Proteins - genetics; Humans; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Polymorphism, Genetic; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Protein-Serine-Threonine Kinases - genetics; Severity of Illness Index; Tumor Suppressor Proteins - genetics
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/j.urology.2005.12.012

ATM is an important protein that protects the genome from double-stranded DNA breaks. Mutations and polymorphisms in the ATM gene have been associated with an increased risk of certain types of malignancies, especially breast cancer. We analyzed tissue from 98 white patients with prostate cancer for the presence of IVS62+60G>A polymorphism in the ATM gene. The frequency of the homozygous IVS62+60G/G, heterozygous IVS62+60G/A, and homozygous IVS62+60A/A was 18.37% (18 of 98), 30.61% (30 of 98), and 51.02% (50 of 98), respectively. Using Fisher’s exact test, we found the polymorphism IVS62+60G>A was not significantly related to age, tumor grade, prostate-specific antigen level, or clinical stage ( P >0.05). No difference was found in relapse-free survival between patients with IVS62+60G/G and those with IVS62+60G/A or IVS62+60A/A ( P = 0.4533). The results of our study indicate that this ATM polymorphism is not associated with the aggressiveness of prostate cancer in white men.